Bioglan Pharma plc

Bioglan are an independent, British-owned group of pharmaceutical companies, focused on dermatology, cardiovascular therapies and development of drug delivery systems. We have focused on a number of carefully chosen therapeutic areas including:
Dermatology - a range of products to treat diseases of the skin and also other therapies applied to or through the skin, including Cetavlon/Cetavlex (for skin infections), Micanol (psoriasis therapy), Benzamycin (acne therapry), Synalar (steroid-responsive dermatoses), Axsain (topical therapy indicated for post-herpetic neuralgia and painful diabetic neuropathy), Zacin (topical therapy for osteo-arthritic pain), Xepin (pruritus associated with eczema), Crystacide/Microcid (skin infections), Anabact (rosacea and deodorising of fungating tumours), and Aveeno (dry skin treatment).
Cardiovascular - niche cardiovascular product, Glytrin, a CFC free sublingual spray containing glyceryl trinitrate for the treatment and prevention of acute attacks of angina pectoris.
Imaging agents - the Group's German affiliate, Golham Bioglan Pharma GmbH, specialises in the development and marketing of imaging agents.

Activity:

- Manufacturing

Product / Technology type(s) covered:

- Drug delivery
- Generics
- Pharmaceuticals / Therapeutics

Therapeutic targets:

- Cardiovascular
- Dermatology

Markets Covered

a. HeadQuarter:

b. Continent(s) active: Europe , North America

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: